Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

HYDROCODONE  FOR PEAK IDENTIFICATION CRS - * NARC (10 MG)

HYDROCODONE FOR PEAK IDENTIFICATION CRS - * NARC (10 MG)

NA

DISCOVER
SOMATROPIN/ DESAMIDOSOMATROPIN RESOLUTION MIXTURE CRS (3 MG)

SOMATROPIN/ DESAMIDOSOMATROPIN RESOLUTION MIXTURE CRS (3 MG)

NA

DISCOVER
EQUINE INFLUENZA SUBTYPE 2 AMERICAN-LIKE/SOUTH AFRICA/4/03 H

EQUINE INFLUENZA SUBTYPE 2 AMERICAN-LIKE/SOUTH AFRICA/4/03 H

NA

DISCOVER
OXITROPIUM BROMIDE IMPURITY DCRS (10 MG)

OXITROPIUM BROMIDE IMPURITY DCRS (10 MG)

95778-01-1

DISCOVER
RITONAVIR CRS (80 MG)

RITONAVIR CRS (80 MG)

155213-67-5

DISCOVER
OXITROPIUM BROMIDE IMPURITY BCRS (15 MG)

OXITROPIUM BROMIDE IMPURITY BCRS (15 MG)

155-41-9

DISCOVER
TESTOSTERONE ISOCAPROATE FOR SYSTEM SUITABILITY CRS (5 MG)

TESTOSTERONE ISOCAPROATE FOR SYSTEM SUITABILITY CRS (5 MG)

15262-86-9

DISCOVER
Moxifloxacin for peak identification

Moxifloxacin for peak identification

186826-86-8

DISCOVER
LORAZEPAM IMPURITY D CRS (15 MG)

LORAZEPAM IMPURITY D CRS (15 MG)

NA

DISCOVER
PACLITAXEL SEMI-SYNTHETIC FORPEAK IDENTIFICATION CRS (10 MG

PACLITAXEL SEMI-SYNTHETIC FORPEAK IDENTIFICATION CRS (10 MG

33069-62-4

DISCOVER
TRIGLYCEROL DIISOSTEARATE CRS(200 MG)

TRIGLYCEROL DIISOSTEARATE CRS(200 MG)

NA

DISCOVER
MIRTAZAPINE FOR SYSTEM SUITABILITY CRS (10 MG)

MIRTAZAPINE FOR SYSTEM SUITABILITY CRS (10 MG)

61337-67-5

DISCOVER